CHRONIC LYMPHOCYTIC LEUKEMIA

This study tests whether a two-shot pneumonia vaccine series (PCV20 and PPSV23) can help people with chronic lymphocytic leukemia (CLL) build a stronger immune defense against pneumococcal infections. About 61 participants, including those who have not yet had CLL treatment and t…

This early-phase study tests an oral drug called AS-1763 in 120 adults with certain blood cancers (CLL/SLL or NHL) that have not responded to at least two prior treatments. The main goals are to find the safest dose and see how well the drug shrinks tumors. Participants take the …

This study tests an experimental drug called ABBV-319 in adults with certain blood cancers (diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia) that have come back or stopped responding to treatment. The main goals are to check the drug's safety, …

This study looks at whether starting treatment early with two drugs (venetoclax and obinutuzumab) is better than waiting until symptoms appear in people newly diagnosed with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. About 247 participants will be rando…

This early-phase trial tests azer-cel, a ready-made CAR T cell therapy, in adults with relapsed or refractory non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and related blood cancers. The goal is to see if the treatment is safe and can shrink or control tumors. About …

This study tests whether adding emavusertib to an approved BTK inhibitor (zanubrutinib) can improve outcomes for people with chronic lymphocytic leukemia (CLL) and other B-cell cancers. About 108 adults with CLL will receive the combination. The goal is to see if the combo can ma…

This study tests a two-step stem cell transplant using lower doses of radiation and chemo before the transplant. The goal is to reduce deaths from the transplant itself while still treating blood cancers like leukemia and lymphoma. About 63 adults will take part. If successful, t…

This study tests a combination of two drugs, nemtabrutinib and pembrolizumab, in 32 people with a rare and aggressive form of blood cancer called Richter transformation. The goal is to see if this drug pair can shrink or kill cancer cells better than current treatments. Participa…

This early-stage study tests a new gene therapy called VNX-101 in about 32 people with blood cancers (like certain leukemias and lymphomas) that have returned or not responded to standard treatments. The therapy aims to help the body's immune system attack cancer cells that have …

This study tests a combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) given for a limited time to people whose chronic lymphocytic leukemia or small lymphocytic lymphoma has come back. The goal is to see if this treatment can control the disease safely. Abou…

This early-phase study tests a drug called mosunetuzumab, alone or with venetoclax, in about 137 adults whose chronic lymphocytic leukemia (CLL) has returned or stopped responding to prior therapy. The main goal is to check safety and find the right dose. Participants must have C…

This study offers ongoing access to the drug ibrutinib for people with certain blood cancers (like chronic lymphocytic leukemia or mantle cell lymphoma) who are already taking it and benefiting. Researchers will track side effects and how the disease changes over time. About 700 …

This study looks at how often high blood pressure happens in people with certain blood cancers (like CLL or lymphoma) who are taking a type of targeted drug called a BTK inhibitor. The goal is to see if carefully managing that high blood pressure can reduce the risk of serious he…

This study looks at people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are already taking a BTKi pill (like ibrutinib). Half will keep taking their current pill alone, while the other half will add a second pill called venetoclax for one year, …

This study tests a combination of two targeted drugs, pirtobrutinib and venetoclax, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has stopped responding to standard BTK inhibitors. The goal is to see if the combo can eliminate …

This study tests whether giving two drugs together—acalabrutinib and obinutuzumab—can control chronic lymphocytic leukemia (CLL) in people who haven't had treatment yet. The goal is to see if patients can stop taking acalabrutinib for a while without the cancer coming back. About…

This study tests whether a combination of three drugs (acalabrutinib, venetoclax, and durvalumab) can help people with Richter transformation, a rare and fast-growing lymphoma that can develop from chronic lymphocytic leukemia (CLL). About 27 adults with CLL or small lymphocytic …

This study tests a one-year treatment plan using two drugs, pirtobrutinib and obinutuzumab, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment before. The goal is to see if this fixed-duration therapy can control the …

This study tests a drug called glofitamab, alone or with other medicines, in people whose chronic lymphocytic leukemia (CLL) has turned into a more aggressive cancer called Richter's transformation. About 70 adults will receive treatment to see if the cancer shrinks or disappears…

This study compares a new drug, BGB-16673, to an existing treatment (pirtobrutinib) in about 500 people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has returned or stopped responding to prior therapy. The main goal is to see if the new drug helps …

This early-stage trial tests a new drug called CC312 for people with certain blood cancers (like lymphoma or leukemia) that have returned or stopped responding to standard treatments. The main goals are to check the drug's safety and find the right dose. About 44 adults will take…

This study tests the drug mosunetuzumab, given alone or with a BTK inhibitor, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if it can clear very small amounts of cancer cells left after previous treatment. About 40 adult…

This study tests a combination of three drugs (zanubrutinib, obinutuzumab, and sonrotoclax) in people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The main goal is to see how many participants achieve undetectable cancer levels…

This study tests a new drug called APG-2575 in people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has come back or stopped responding to other treatments. About 75 adults will take the drug alone to see if it can shrink tumors and control the dise…

This study tests a new treatment for people with advanced B-cell lymphoma or leukemia that has returned or not responded to standard therapy. Researchers take a patient's own T-cells, add a special receptor (CAR) that targets the CD19 protein on cancer cells, and also add extra s…

This study tests whether adding a new drug called roginolisib to the standard combination of venetoclax and rituximab can better control relapsed or refractory chronic lymphocytic leukemia (CLL). About 64 adults who have already tried at least two prior treatments will receive th…

This study compares a new oral drug, nemtabrutinib, against two standard treatments (ibrutinib or acalabrutinib) for people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. About 1,200 participants will be randomly assigned to receive nemtabrutinib or a …

This study tests a combination of the drug polatuzumab vedotin with standard chemotherapy for people with Richter's transformation, an aggressive lymphoma that can develop from chronic lymphocytic leukemia (CLL). About 20 adults will receive up to six cycles of treatment. The mai…

This study tests whether adding the drug epcoritamab after standard treatment can make leukemia undetectable in people with CLL or SLL. About 22 adults who have already received a BTKi drug (with or without obinutuzumab) for at least 12 months will get epcoritamab for 12 cycles. …

This study compares two treatments for people with early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are at high risk of their disease getting worse. One group gets acalabrutinib alone, the other gets acalabrutinib plus obinutuzumab. The goal …

This study tests whether taking nicotinamide (a form of vitamin B3) twice daily can reduce the number of new non-melanoma skin cancers in people with chronic lymphocytic leukemia (CLL) who have already had at least one such skin cancer. About 86 participants will be randomly assi…

This study tests whether adding venetoclax to ongoing ibrutinib or acalabrutinib treatment can clear remaining leukemia cells in people with high-risk chronic lymphocytic leukemia (CLL). About 90 participants who have been on ibrutinib or acalabrutinib for at least a year will re…

This study compares two different drug combinations for people with untreated chronic lymphocytic leukemia (CLL). One group gets sonrotoclax plus zanubrutinib, the other gets venetoclax plus acalabrutinib. The goal is to see which combo works better at controlling the disease and…

This early-phase study tests a new drug called SGR-1505 in about 98 adults with various B-cell blood cancers (like lymphomas and leukemia). The main goals are to find the safest dose and understand side effects. Participants will receive the drug alone, and researchers will monit…

This study tests a new drug, pirtobrutinib, against the standard drug ibrutinib for people with chronic lymphocytic leukemia or small lymphocytic lymphoma. About 662 participants, some previously treated and some not, will receive one of the two drugs to see which works better an…

This study compares two schedules of the drug venetoclax (taken either in cycles or daily) when combined with acalabrutinib for people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if intermittent dosing works as well as continuous …

This study tests a new type of CAR T-cell therapy for adults with certain blood cancers (B-cell lymphoma or leukemia) that have come back or not responded to treatment. The therapy uses specially 'fit' immune cells to better attack cancer. The goal is to find the safest dose and …

This study tests an experimental pill called LP-118 in up to 100 adults with blood cancers that have come back or not responded to treatment. The main goal is to find a safe dose and see how the body processes the drug. Early signs of effectiveness will also be tracked, but this …

This study tests three different doses of pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer came back after treatment with a BTK inhibitor. About 249 participants will take part. The goal is to see which dose works be…

This early-stage trial tests a combination of three drugs (tafasitamab, acalabrutinib, and obinutuzumab) in people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if the combination is safe and can kill more can…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) who were already in an earlier trial. About 279 participants will continue their treatment or follow-up visits. The main goal is to t…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia or non-Hodgkin lymphoma. About 787 adults who already took part in earlier pirtobrutinib studies can join. They will keep getting the drug or have follow-up visits to mo…

This study tests whether a new drug, sonrotoclax, combined with an antibody therapy works better than the current standard treatment for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or stopped responding to prior therapy. About 630 par…

This study tests two drug combinations—acalabrutinib plus venetoclax or acalabrutinib plus obinutuzumab—in people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see which combination better reduces cancer cells to undetectable levels in …

This study tests different ways to start a drug called venetoclax (given with other medicines) in people with untreated chronic lymphocytic leukemia (CLL). The goal is to find the safest dosing schedule to reduce the risk of a serious side effect called tumor lysis syndrome. Abou…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already been treated with other therapies. It is open to 150 participants who completed a previous pirtobrutinib study…

This study tests whether a faster, hospital-based dose increase of the drug sonrotoclax, given after initial treatment with zanubrutinib or rituximab, is safe and tolerable for people with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lympho…

This study tests a personalized treatment plan for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior therapy. Participants first receive a combination of two drugs (venetoclax and obinutuzumab). If the …

This study tests a new drug, BGB-16673, against standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has already been treated with both BTK and BCL2 inhibitors. About 250 participants will be randomly assigned to …

This study tests a new drug called BGB-16673 in people with several types of B-cell blood cancers (like lymphoma and leukemia) that have come back or not responded to other treatments. The trial has two parts: first, finding the safest dose, and then testing how well that dose sh…

This study tests a new drug, BGB-16673, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding to prior treatments, especially a type of drug called a BTK inhibitor. About 150 participants will receive…

This study tests whether adding a drug called epcoritamab to the usual two-drug treatment (venetoclax and obinutuzumab) can make cancer disappear more completely in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 33 adults will …

This study tests whether giving yearly pneumococcal vaccines to people with chronic lymphocytic leukemia (CLL) offers better protection than the current 5-year schedule. About 80 untreated CLL patients will receive either yearly or standard vaccines. The goal is to see if more fr…

This study tests a vaccine (CMV-MVA Triplex) given to stem cell donors to boost their immunity against cytomegalovirus (CMV). When the donor's stem cells are transplanted into the patient, that immunity is passed along, potentially preventing CMV infection. The trial involves 216…

This early-phase trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent active infection after transplant. About 46 people with various blood cancers or disorders will take part. The goal i…

This study is for people starting a type of blood cancer medication called BTK inhibitors. Researchers want to see if a small implanted heart monitor can detect irregular heartbeats (like atrial fibrillation) that may be caused by the drug. About 50 participants will get the moni…

This study looks at how chronic lymphocytic leukemia (CLL) cells use nutrients like glucose and glutamine compared to normal cells. Researchers will give participants a special tracer and measure its breakdown in blood cells. The goal is to understand CLL cell metabolism better, …

This study follows 500 people who received CAR-T cell therapy for blood cancers like leukemia, lymphoma, or multiple myeloma. Researchers will check for new cancers or other long-term side effects over 15 years. The goal is to understand the lasting safety of this treatment, not …

This study aims to understand the genetic changes that happen in chronic lymphocytic leukemia (CLL) cells when patients take the drug venetoclax. Researchers will enroll 75 adults with CLL that has come back or not responded to at least one prior treatment. Participants receive v…

This study looks at whether starting treatment early for people with high-risk chronic lymphocytic leukemia (CLL) is worth the cost compared to waiting. Researchers will track medical visits, tests, and hospital stays over 10 years. The goal is to see which approach gives better …

This study is observing adults with Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, or follicular lymphoma who are taking the drug zanubrutinib as part of their normal treatment. Researchers want to see how often patients need hospital care …

This study looks at how the immune system of people with lymphoma responds to flu and COVID vaccines. Researchers will measure antibody levels and immune cells over time in 200 participants with different types of lymphoma and compare them to healthy people. The goal is to better…

This study collects blood and tissue samples from 2000 people—some with cancer, some without—to build a reference set for evaluating new blood tests that aim to detect multiple cancers early. Researchers will use these samples to measure how accurate the tests are at telling canc…

This study looks at whether CAR-T therapy, a treatment for certain blood cancers, reduces the protection vaccines give against diseases like measles and mumps. About 45 adults with multiple myeloma or non-Hodgkin lymphoma will have their blood tested before and after CAR-T therap…

This study measures how chronic lymphocytic leukemia (CLL) patients feel and function while taking the drug acalabrutinib in everyday life, not just in a controlled trial. Researchers will review medical records of 120 adults in France who started acalabrutinib, tracking their qu…

This study tracks 50 adults with chronic lymphocytic leukemia (CLL) who are starting acalabrutinib alone (no other cancer drugs) to see how long they stay on treatment and why they might stop. It collects real-world data on effectiveness and side effects, filling a knowledge gap …

This study looks at how the bone marrow makes blood cells in people with monoclonal B-cell lymphocytosis (MBL) or chronic lymphocytic leukemia (CLL) compared to healthy adults of the same age. Researchers want to understand if these conditions affect the bone marrow's ability to …

This study follows 2000 people with chronic lymphocytic leukemia (CLL) to see how different treatment plans affect how long they live. Researchers will track patients who received their first treatment in earlier clinical trials. The goal is to learn which treatment sequences wor…

This study is collecting blood, bone marrow, and lymph node samples from 60 people with chronic lymphocytic leukemia (CLL) who are taking or about to take a new type of drug called a BTK degrader. The goal is to understand why some patients' cancer stops responding to these drugs…

This study collects blood and tissue samples along with medical information from up to 2750 people with chronic lymphocytic leukemia (CLL) or related conditions. Researchers will analyze the samples to find new genetic markers and better understand what causes CLL and how it beha…

This study is collecting basic survival and complication information from 2000 people receiving stem cell transplants for blood cancers or immune diseases. The goal is to build a database that helps doctors and researchers better understand long-term outcomes and improve future t…